Skip to main content
OpenTrials
Completed

NCT Number: NCT00476788

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII) therapy in young children using a novel delivery method in the form of a self-contained, lightweight, and disposable insulin pump unit controlled with a wireless handheld device. The outcomes of interest are the feasibility and potential metabolic benefits of this approach. We anticipate that the initiation of this CSII device in the immediate post-diagnosis period in this population will result in good glycemic control and greater parental satisfaction when compared to intensive insulin injection therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital

Birmingham, Alabama, 35233, United States

About this study

The incidence of type 1 diabetes (T1DM) is on the rise worldwide, especially in children younger than six years of age. Glycemic control using multiple daily injection (MDI) therapy can be difficult to achieve and maintain in the very young, especially in the immediate post-diagnosis period. This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII) therapy in young children using a novel delivery method in the form of a self-contained, lightweight, and disposable insulin pump unit controlled with a wireless handheld device. The outcomes of interest are the feasibility, safety, and potential metabolic benefits of this approach. We will recruit 14 pediatric patients, aged one to ten years, from a pool of all children newly diagnosed with T1DM admitted to the Children's Hospital of Alabama to use the pump.General diabetes education and CSII-specific training will take place in a series of outpatient sessions with the PI and study nurse. Pump therapy will be initiated within two months of diagnosis providing that all requisite education and training has been successfully completed. Data will be collected for both study group and control group patients for six months via phone calls and monthly clinic visits. Areas which will be evaluated include glycemic control, residual endogenous insulin secretion, frequency of severe adverse events, parental distress, insulin needs, and physical growth. While initiating CSII in the immediate post-diagnosis period in this population may be initially time-intensive, it is anticipated that it will ultimately become time-saving because of the greater ease in blood sugar management.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 1 through 10 years of age
  • Patients present to the Children's Hospital of Alabama with a new diagnosis of type 1 diabetes
  • Patients may be admitted to the inpatient unit
  • OR from the ER
  • OR or from an outside facility to Children's Hospital
  • Or seen in our outpatient clinic for the first time having been diagnosed at an outside facility
  • If patients are recruited from the outside facility in our outpatient clinic, the diagnosis must have been made within two weeks of the visit. Twenty patients and twenty control subjects will be recruited over a six-month period.

Exclusion criteria

  • Patients with diabetes due to other causes (neonatal diabetes, pancreatitis, cystic fibrosis, etc.)
  • Patients will younger than 2 years of age
  • Patients older than 8 years of age
  • Lack any presence of other systemic disease(s), such as neoplastic disease or renal failure.
  • Patients must have adequate parental support and stable home environment (e.g. children in foster care or with a history of suspected abuse or neglect would be excluded).

Treatment and study plan

Omnipod Insulin Management System

Device

Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus

Other names: Tubeless insulin pump

Primary outcomes

  1. Mean Glycated Hemoglobin (A1c)

    Time frame: 6.9 months (average)

    Measure of glycemic control (A1c) over preceding 8 weeks. Normal for a patient between ages 1 and 10 years would be 7.0-8.5%.

Secondary outcomes

  1. Number of Reported Adverse Events

    Time frame: 6.9 months (average)

    adverse events are defined as a change from baseline

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Registry information

Official study title

Fast Track Continuous Subcutaneous Insulin Infusion (CSII) in Children With Newly Diagnosed Type 1 Diabetes Mellitus: An Evaluation of a Novel CSII Device in the Immediate Period Following Diagnosis of Type 1 Diabetes (T1DM)

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
May 22, 2007
Registry last updated
Apr 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.